Document Detail


Metabolic and immunologic derangements in cardiac cachexia: where to from here?
MedLine Citation:
PMID:  16819578     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The onset of cardiac cachexia is characterized by a defined severe weight loss in patients with advanced chronic heart failure and it predicts an increased mortality in these patients. Recent studies with potential therapeutics investigated the effects and efficiency of beta-blockers, ghrelin, or ghrelin-agonists in cachexia. These and other new studies, like the influence of heart transplantation on cardiac cachexia, give prospect into potential therapeutic options in the future. General aim of the treatment strategy is to prevent the onset and retard the progress of cachexia. This could be achieved by modifying the metabolic, neurohormonal and immune system abnormalities, e.g. with beta-blockers and angiotensin-converting enzyme inhibitors. However, these alterations interact in a complex pathophysiological process, which is supposed to end in a vicious circle and thereby the wasting process is further promoted. To interrupt this, an early start of therapy is important to decelerate the development of cardiac cachexia. Many further investigations are needed to find out more about the pathophysiological pathways, to confirm the previous results, and to evaluate new therapeutics.
Authors:
Sabine Strassburg; Stefan D Anker
Related Documents :
3041118 - An in vivo cumulative dose-response assay of the myocardial beta-adrenoceptor system.
21929568 - Effects of left ventricular function on the exercise capacity in patients with repaired...
21831398 - Incidence of various cardiac arrhythmias and conduction disturbances due to high dose i...
21914028 - Non-surgical left atrial appendage closure for stroke prevention in atrial fibrillation.
22493608 - Constrictive pericarditis as a never ending story: what's new?
16859778 - Near-fatal incident on routine induction of ventricular fibrillation at the replacement...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Heart failure reviews     Volume:  11     ISSN:  1382-4147     ISO Abbreviation:  Heart Fail Rev     Publication Date:  2006 Mar 
Date Detail:
Created Date:  2006-07-05     Completed Date:  2006-11-21     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9612481     Medline TA:  Heart Fail Rev     Country:  United States    
Other Details:
Languages:  eng     Pagination:  57-64     Citation Subset:  IM    
Affiliation:
Dept. of Cardiology, Applied Cachexia Research, Charité, Campus Virchow-Klinikum, Berlin, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aldosterone Antagonists / pharmacology,  therapeutic use
Angiotensin-Converting Enzyme Inhibitors / pharmacology,  therapeutic use
Cachexia / drug therapy,  immunology*,  metabolism*,  physiopathology
Dietary Supplements
Disease Progression
Exercise / physiology
Heart Failure / drug therapy,  immunology*,  metabolism*,  physiopathology
Humans
Oxidative Stress / physiology
Prognosis
Spironolactone / pharmacology,  therapeutic use
Chemical
Reg. No./Substance:
0/Aldosterone Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 52-01-7/Spironolactone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Macro- and micronutrients in African-Americans with heart failure.
Next Document:  Micronutrients and their supplementation in chronic cardiac failure. An update beyond theoretical pe...